European journal of cancer (Oxford, England : 1990) · 2025
Long-term recurrence patterns in rectal cancer after neoadjuvant therapy: 25-years of real-world data.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maerten Pieter, Defraene Gilles, Wolthuis Albert, Schraepen Cédric, Bislenghi Gabriele, De Hertogh Gert, Debrun Lynn, Dierick Evelien, Dresen Raphaëla, Leclercq Philippe, Penninckxc Freddy, Rasschaert Gertjan, Sagaert Xavier, Tejpar Sabine, Van Herpe Filip, Dekervel Jeroen, Van Cutsem Eric, D'Hoore André, Haustermans Karin
Аннотация
BACKGROUND: The management of locally advanced rectal cancer has significantly evolved over the past 25-years, most recently with the adoption of total neoadjuvant therapy (TNT). Nevertheless, optimal treatment selection for individual patients remains challenging. This study evaluated recurrence patterns in rectal cancer to improve risk stratification and guide neoadjuvant treatment decisions in the TNT era.
METHODS: We conducted a prospective cohort study including 850 rectal cancer patients treated with neoadjuvant radio- and chemotherapy over a 25-year period.
FINDINGS: After a median follow-up of 12 years, 5-year overall survival (OS) and disease-free survival (DFS) were 86.8 % and 75.5 %. Recurrence occurred in 167 patients (19.6 %), including 31 (3.6 %) with locoregional recurrence (LRR), 158 (18.6 %) with distant metastases (DM) and 22 (2.6 %) with both. Five-year recurrence-free survival (RFS), DM-free survival (DMFS) and LRR-free survival (LRFS) were 76.9 %, 77.8 % and 85.3 %. Mesorectal fascia involvement (p = 0.006) and extra-mural vascular invasion (p = 0.028) were associated with recurrence on univariable analysis, although their impact diminished after adjusting for neoadjuvant treatment. Independent predictors of DM were lymphovascular invasion (p < 0.001), perineural invasion (p = 0.004), positive circumferential resection margin (p = 0.046) and higher lymph node ratio (LN-ratio) (p < 0.001). Tumor diameter (p = 0.025) and LN-ratio (p = 0.047) independently predicted LRR. Early recurrence was associated with worse OS, although post-recurrence survival did not differ significantly.
CONCLUSION: Histopathological features and tumor response to neoadjuvant therapy are strong predictors of recurrence risk in rectal cancer. Identifying reliable baseline biomarkers of treatment response is essential to refine patient risk stratification and personalize neoadjuvant treatment strategies in the TNT era.
METHODS: We conducted a prospective cohort study including 850 rectal cancer patients treated with neoadjuvant radio- and chemotherapy over a 25-year period.
FINDINGS: After a median follow-up of 12 years, 5-year overall survival (OS) and disease-free survival (DFS) were 86.8 % and 75.5 %. Recurrence occurred in 167 patients (19.6 %), including 31 (3.6 %) with locoregional recurrence (LRR), 158 (18.6 %) with distant metastases (DM) and 22 (2.6 %) with both. Five-year recurrence-free survival (RFS), DM-free survival (DMFS) and LRR-free survival (LRFS) were 76.9 %, 77.8 % and 85.3 %. Mesorectal fascia involvement (p = 0.006) and extra-mural vascular invasion (p = 0.028) were associated with recurrence on univariable analysis, although their impact diminished after adjusting for neoadjuvant treatment. Independent predictors of DM were lymphovascular invasion (p < 0.001), perineural invasion (p = 0.004), positive circumferential resection margin (p = 0.046) and higher lymph node ratio (LN-ratio) (p < 0.001). Tumor diameter (p = 0.025) and LN-ratio (p = 0.047) independently predicted LRR. Early recurrence was associated with worse OS, although post-recurrence survival did not differ significantly.
CONCLUSION: Histopathological features and tumor response to neoadjuvant therapy are strong predictors of recurrence risk in rectal cancer. Identifying reliable baseline biomarkers of treatment response is essential to refine patient risk stratification and personalize neoadjuvant treatment strategies in the TNT era.